Amyloidosis is not cancer, but it can look like cancer on imaging and sometimes occurs alongside it
Amyloidosis and cancer are two separate diseases, but the distinction matters because it changes how doctors treat you and what your prognosis looks like. Amyloidosis happens when abnormal proteins called amyloid fold into clumps and deposit in your organs—heart, kidneys, nerves, liver. Cancer happens when cells grow without control. The two can coexist: some blood cancers like multiple myeloma produce the abnormal proteins that cause amyloidosis, and amyloidosis itself does not turn into cancer. But because amyloidosis can show up on scans as masses or thickening, and because it causes organ damage that mimics other serious diseases, it sometimes gets mistaken for cancer at first.
The confusion is understandable. Both amyloidosis and cancer can cause weight loss, fatigue, swelling, and organ failure. Both can show abnormal tissue on a CT or MRI. But the treatment is completely different. Cancer treatment targets the malignant cells themselves. Amyloidosis treatment targets the source of the abnormal proteins—which might be a blood disorder, an inherited mutation, or chronic inflammation—and tries to slow or stop new amyloid from forming.
Key Takeaways
- Amyloidosis is a protein-folding disease, not a cancer, though some blood cancers can cause amyloidosis as a side effect.
- A diagnosis of amyloidosis requires a tissue biopsy showing amyloid deposits under a microscope, not just imaging findings.
- Some types of amyloidosis are inherited, some are caused by chronic kidney disease or inflammation, and some are linked to blood disorders like multiple myeloma.
- Treatment depends on the type of amyloidosis and its cause—chemotherapy is used only when an underlying blood cancer is driving the amyloid production.
Why amyloidosis and cancer get confused
Amyloidosis can produce findings on imaging that resemble cancer. A thickened heart wall, enlarged organs, or nodular deposits in the liver might look like tumors on a CT scan. Doctors may order a biopsy to rule out malignancy, and that biopsy is actually the right move—it is the only way to know for certain what you are dealing with.
The biopsy is the turning point. Under a microscope, amyloid has a distinctive appearance: it stains pink with standard dyes and shows a characteristic "apple-green" color under polarized light when stained with Congo red. Cancer cells look entirely different. Once the pathologist identifies amyloid, the diagnosis shifts away from cancer, and the focus moves to finding what is causing the amyloid to form.
Types of amyloidosis and their causes
Amyloidosis comes in several forms, and the cause determines treatment. AL amyloidosis (light-chain amyloidosis) happens when bone marrow cells produce abnormal immunoglobulin light chains that fold into amyloid. This is not cancer itself, but it is a blood disorder—the bone marrow is malfunctioning. About 10 to 15 percent of people with AL amyloidosis also have multiple myeloma, a blood cancer. When myeloma is present, treating the cancer with chemotherapy can slow amyloid formation.
AA amyloidosis develops from chronic inflammation or chronic kidney disease. Infections, rheumatoid arthritis, inflammatory bowel disease, or long-term dialysis can trigger it. This type is not linked to cancer and does not require cancer treatment.
Hereditary amyloidosis (transthyretin amyloidosis, or ATTR) is caused by inherited mutations in the transthyretin gene. It is not cancer and is not caused by cancer. Newer medications can slow the progression by stabilizing the transthyretin protein or reducing its production.
When amyloidosis occurs with blood cancer
Multiple myeloma and light-chain amyloidosis can occur together because both involve abnormal bone marrow cells. When they do, the myeloma is treated with chemotherapy, targeted drugs, or stem cell transplant—the same treatments used for myeloma alone. The amyloid deposits do not disappear immediately, but slowing or stopping new protein production allows the body to gradually clear some of the existing amyloid.
Other blood cancers, like Waldenström macroglobulinemia or lymphoma, can also produce amyloid-forming proteins, though this is less common. In these cases, treating the underlying cancer is the primary goal, and amyloid management follows.
How amyloidosis is diagnosed
Diagnosis requires tissue confirmation. Doctors may biopsy the heart, kidney, nerve, or other affected organ, or they may take a fat pad biopsy from under the skin—a simpler procedure that often shows amyloid if it is present. Blood and urine tests can detect abnormal light chains or other markers. Imaging like echocardiography or cardiac MRI shows organ damage but cannot diagnose amyloidosis on its own.
Once amyloid is confirmed, further testing identifies the type. This might include genetic testing for hereditary forms, blood tests for light chains or inflammatory markers, or specialized protein analysis. Knowing the type is essential because it determines whether the cause is an inherited mutation, a blood disorder, chronic inflammation, or something else.
Treatment approaches differ from cancer treatment
If amyloidosis occurs without an underlying cancer, treatment focuses on slowing amyloid formation and managing organ damage. For AL amyloidosis without myeloma, chemotherapy drugs like bortezomib or melphalan may be used to suppress the abnormal bone marrow cells producing light chains. For hereditary ATTR amyloidosis, newer drugs like tafamidis stabilize the protein and slow its conversion to amyloid. For AA amyloidosis, the goal is controlling the underlying inflammation or kidney disease.
Heart failure, kidney failure, and nerve damage from amyloid deposits are managed with standard therapies—diuretics for fluid overload, dialysis if kidneys fail, pacemakers if the heart rhythm is affected. The organ damage itself does not respond to cancer treatment because it is not caused by cancer cells.
Prognosis and what to expect
Prognosis for amyloidosis varies widely depending on the type, which organs are affected, and how early it is caught. Cardiac amyloidosis is more serious than renal amyloidosis. Hereditary forms progress more slowly than AL amyloidosis in many cases. Newer treatments have improved outcomes, particularly for ATTR amyloidosis, but amyloidosis remains a serious condition that requires ongoing monitoring and management.
If you have been diagnosed with amyloidosis, your doctors will monitor organ function regularly with blood tests, imaging, and sometimes biopsies to track whether the disease is stable, progressing, or responding to treatment. This is different from cancer surveillance, which looks for recurrence or spread of malignant cells.
Frequently Asked Questions
Can amyloidosis turn into cancer?
No. Amyloidosis is a protein-folding disease and does not transform into cancer. However, some blood cancers like multiple myeloma can cause amyloidosis as a complication. If you have amyloidosis, your risk of developing an underlying blood disorder is higher than the general population, which is why doctors monitor blood counts and protein levels.
If I have multiple myeloma, will I definitely get amyloidosis?
No. Most people with multiple myeloma do not develop amyloidosis. About 10 to 15 percent do, depending on the type of abnormal protein their myeloma produces. Your doctor can test for light chains in your blood and urine to assess your risk.
Is amyloidosis hereditary?
Some types are. Hereditary transthyretin amyloidosis (ATTR) is caused by inherited mutations and runs in families. AL amyloidosis and AA amyloidosis are not inherited, though having a family member with AL amyloidosis may slightly increase your risk. Genetic testing can determine whether your amyloidosis is hereditary.
What does a biopsy show to confirm amyloidosis instead of cancer?
A biopsy stained with Congo red dye shows amyloid deposits with a distinctive apple-green appearance under polarized light. Cancer cells look completely different under the microscope. The pathologist can also perform protein typing to identify which type of amyloid is present.
Can chemotherapy cure amyloidosis?
Chemotherapy does not cure amyloidosis, but it can slow progression by reducing the production of abnormal proteins that form amyloid. In AL amyloidosis linked to a blood disorder, chemotherapy targets the bone marrow cells making the abnormal proteins. Newer drugs like tafamidis for hereditary ATTR work differently—they stabilize the protein rather than reducing its production.